The most common indications for digoxin are atrial fibrillation and atrial flutter with rapid ventricular response, though beta blockers and/or calcium channel blockers are a better first choice. There is tentative evidence that digoxin may increase the risk of death, though another meta-analysis reports no change in mortality. High ventricular rate leads to insufficient diastolic filling time. By slowing down the conduction in the AV node and increasing its refractory period, digoxin can reduce the ventricular rate. The arrhythmia itself is not affected, but the pumping function of the heart improves, owing to improved filling.

The Abbkine Digoxin Mouse Monoclonal Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. The antibody has been validaed in ELISA.

Abbkine supplies below price/size: $100/30μl, $220/100μl, $360/200μl of Mouse Anti-Digoxin Monoclonal Antibody at https://www.abbkine.com/product/digoxin-monoclonal-antibody-abm40256.

Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.